Oseltamivir Update

Sign in or subscribe to listen

No me gusta!

The flash player was unable to start. If you have a flash blocker then try unblocking the flash content - it should be visible below.

Ian L. -

In the Cochrane Trial Report by Jefferson et Al 2014-Oseltamivir as prophylaxis REDUCED Symptomatic Influenza by an RD of 3.05% in exposed patients and in household contacts by an RD of 13.6% .
On December 14 2022 the CDC USA recommended oseltamivirr for patients at high risk who had contracted influenza and as early as possible (within hours or on stat presentation ) and for Hospitalised Patients if suspected or lab confirmed
Outpatients at increased risk of influenza complications
For patients with progressive or severe influenza
Patients who are pregnant , less than two weeks post partum or immunocompromised
Children less than 5 years of age
In Institutional Settings as early treatment or post exposure prophylaxis
If Oseltamivir is unavailable baloxavir zanamvir or IV Peramivir can be used .
In Victoria Australia for Covid 19 very early use that is within 24 hours of Paxlovid found patients over 70 and at risk were 72% less likely to die and with Molnupiravir patients over 70 and at risk were 54% less likely to die .
Like Remdesivir used in hospital for a Year in 2020 was found to reduce death by 87% in at risk patients if used much earlier in the first 7 days of illness .

To join the conversation, you need to subscribe.

Sign up today for full access to all episodes and to join the conversation.

To download files, you need to subscribe.

Sign up today for full access to all episodes.
EM:RAP 2022 Breaking News December 20th: Oseltamivir Update Full episode audio for MD edition 9:21 min - 11 MB - M4A